NOV 2 3 2010 W

Docket No.: 58142(45858)

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Martin A. Smith et al.

Application No.: 10/530,146

Confirmation No.: 2874

Filed: March 31, 2005

Art Unit: 1637

For:

METHODS AND MATERIALS FOR USING CHEMICAL COMPOUNDS AS A TOOL FOR NUCLEIC ACID STORAGE ON MEDIA OF NUCLEIC ACID PURIFICATION SYSTEMS

Examiner: J. Tung

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir/Madam:

In accordance with 37 CFR 1.97, Applicant(s) hereby make of record the following additional document. A full copy of the document required under 37 CFR 1.98(a)(2) accompany this statement.

Applicant(s) has become aware of the following European Patent Office Letter, mailed on 13 September 2010, containing Opponents Response to the Proprietor's Brief in the European Opposition related to European Patent No. EP1563091, which is related to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submits this document for the Examiner's consideration.

Applicants previously provided a copy of this European Opposition with the Supplemental Information Disclosure Statement filed on November 20, 2009.

An English translation of the European Opposition is now provided herewith.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be

Application No.: 10/530,146 2 Docket No.: 58142(45858)

construed *per se* as a representation that such document is prior art. Moreover, Applicant(s) understand(s) the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed after the mailing date of a Final-Office Action or Notice of Allowance, whichever occurred first, but on or before payment of the Issue Fee (37 CFR 1.97(d)). Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered.

Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 58142(45858).

Dated: November 23, 2010

Respectfully submitted,

Kathryn A. Piffat, Ph.D., Els Registration No.: 34,901

EDWARDS ANGELL PALMER & DODGE

LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 517-5516

Attorneys/Agents For Applicant